Compare Cassava Sciences Inc (FLNA) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Manulife Financial Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Manulife Financial Corporation trades at $43.58 (market cap $69.26B). The key difference: Manulife Financial Corporation is far larger — about 1757.9× Cassava Sciences Inc's market cap, and Manulife Financial Corporation pays a 3.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Manulife Financial Corporation for 119 Days on average.
| FLNA | MFC | |
|---|---|---|
Market Cap | $39.40M | $69.26B |
Volume | 759,018 | 1,347,387 |
Sector | Health | Financials |
52-Week High | $4.64 | $44.77 |
52-Week Low | $0.68 | $31.64 |
Typical Hold Time | 37 Days | 119 Days |
Enterprise Value | -$43.28M | $64.51B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Manulife Financial (MFC) trades at $42.12, down 1.89% today, with a bearish technical outlook despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and others highlight confidence, while analyst consensus remains positive with 57% buy ratings.
MFC presents a mixed outlook: strong operational performance and dividend yield support upside, but technical indicators signal near-term pressure. Key risks include debt levels and market volatility, while opportunities lie in Asia growth and reinsurance deals. The stock trades above the consensus price target of $34.24, suggesting cautious optimism with execution-dependent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
